{"organizations": [], "uuid": "00b2dadf6bbeda24383f52bad57bcb0ebddd7740", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 6, "shares": 6, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/healthNews\r", "section_title": "Reuters: Health News", "url": "https://www.reuters.com/article/us-bellicum-pharms-fda/bellicums-cancer-drug-trials-on-clinical-hold-shares-tumble-idUSKBN1FJ325", "country": "US", "domain_rank": 408, "title": "Bellicum's cancer drug trials on clinical hold, shares tumble", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-31T00:45:00.000+02:00", "replies_count": 0, "uuid": "00b2dadf6bbeda24383f52bad57bcb0ebddd7740"}, "author": "", "url": "https://www.reuters.com/article/us-bellicum-pharms-fda/bellicums-cancer-drug-trials-on-clinical-hold-shares-tumble-idUSKBN1FJ325", "ord_in_thread": 0, "title": "Bellicum's cancer drug trials on clinical hold, shares tumble", "locations": [], "entities": {"persons": [{"name": "bellicum", "sentiment": "negative"}, {"name": "sai sachin ravikumar", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "bellicum pharmaceuticals inc", "sentiment": "none"}, {"name": "akankshita", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Reuters) - Bellicum Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of the companyâ€™s experimental cancer drug after three cases of brain disease linked to head trauma.\nShares of the Houston-based drug developer fell 48 percent to $5.26 in after-hours trading on Tuesday.\nThe company said the FDA had deemed the cases of brain disease as possibly being related to its cancer drug, BPX-501.\nBellicum said it would work closely with the FDA to address concerns.\nThe clinical hold does not affect another trial testing the same drug in Europe.\nThe company last year moved its planned submission of a European marketing application for the drug to 2019 from a previous expectation of mid-2018.\nReporting by Akankshita; Editing by Sai Sachin Ravikumar\n ", "external_links": [], "published": "2018-01-31T00:45:00.000+02:00", "crawled": "2018-01-31T00:58:50.017+02:00", "highlightTitle": ""}